Biohaven (BHVN) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sarepta Therapeutics (SRPT) has outperformed Biohaven (BHVN) over the past year, losing 22.1% versus a loss of 22.2%. Sarepta Therapeutics is the larger company by market cap ($1.92 billion vs $1.80 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | SRPT |
|---|---|---|
| Share price | $11.93 | $18.21 |
| Market cap | $1.80B | $1.92B |
| 1-day change | +0.42% | +4.06% |
| YTD return | +5.67% | -15.38% |
| 1-year return | -22.23% | -22.11% |
| 5-year return | — | -78.37% |
| Forward P/E | — | 7.55 |
| EPS (TTM) | $-4.56 | $-1.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.57 | $24.68 |
| 52-week low | $7.48 | $14.68 |
| Distance from 52-week high | -35.74% | -26.22% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +78.29% | +19.33% |
| Average volume | 2.62M | 2.99M |
| Shares outstanding | 151.04M | 105.63M |
| Employees | 274 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
BHVN vs SRPT FAQ
Which is bigger, Biohaven or Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.92B compared with $1.80B for Biohaven (BHVN).
Which stock has performed better over the past year, BHVN or SRPT?
SRPT returned -22.11% over the past 12 months, compared with -22.23% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.